ClinicalTrials.gg
CompletedNCT01546558Updated Jul 11, 2012

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

A Phase 1 interventional study of Metformin and Ranolazine in Type 2 Diabetes Mellitus, sponsored by Gilead Sciences. Completed at 1 site in United States. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-07-11.

Sponsored by Gilead Sciences · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
237th of 287
25 · median 100
Started
2012
with 22 others
Phase 1
55 of 293
2 open now
Registered
147th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 237th largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 55 in phase 1, and was the 147th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of steady-state ranolazine 500 mg bid on the steady state pharmacokinetics (PK) of metformin in subjects with type 2 diabetes mellitus (T2DM).

Read the detailed description

The primary objective of this study is as follows:

  • To evaluate the effect of steady-state ranolazine 500 mg twice daily (bid) on the steady state pharmacokinetics (PK) of metformin in subjects with T2DM.

The secondary objectives of this study are as follows:

  • To examine the safety and tolerability of metformin when co administered with ranolazine 500 mg bid at steady-state in subjects with T2DM.
  • To determine the steady-state PK of ranolazine 500 mg bid in subjects with T2DM receiving metformin.
03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Metformin
  • Ranolazine
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, 30 to 65 years old, inclusive
  • Documented history of T2DM
  • 6.5%-10%, inclusive
  • Fasting serum glucose ≤ 270 mg/dL at Screening
  • Fasting C-peptide ≥ 1 ng/mL at Screening
  • Stable metformin monotherapy (metformin ≥ 1500 mg total daily dose for at least 4 weeks prior to Screening)
  • (BMI) 25 to 40 kg/m2, inclusive, at Screening
  • > 80 mL/min at Screening
  • Females of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1 and must agree to use highly effective methods from Screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes Mellitus (T1DM)
  • Use of insulin therapy \< 3 months prior to Screening
  • History of ketoacidosis, ketosis-prone diabetes, or lactic acidosis
  • complications of diabetes
  • History of hypoglycemia
  • Any non-insulin antidiabetic therapy (other than metformin) \< 2 months prior to Screening
  • Any clinically significant cardiovascular event \< 2 months prior to Screening
  • Clinically significant, inadequately controlled, or unstable hypertension
  • Hospitalization \< 2 months prior to Screening or major surgery \< 3 months prior to Screening
  • History of gastrointestinal disease or surgery that could impact drug absorption
  • History of substance of alcohol or substance abuse
  • Positive urine drug screen for drugs of abuse
  • Positive alcohol breath test
  • Any other clinically significant existing medical or psychiatric condition or one requiring further evaluation
  • Treatment with selected medications
  • \< 12 g/dL for males; or \< 11 g/dL for females at Screening
  • (ALT) or aspartate aminotransferase (AST) > 2.5x
  • Clinically significant history of hepatic disease or evidence of hepatic impairment
  • Positive blood screen for or
  • > 500 msec at Screening
  • Females who are pregnant or are breastfeeding
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Metformin, Ranolazine

    Single cohort, 2-period study: * Period 1, metformin 1000 mg bid on Days 1-5 * Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10

    Drug: Metformin · Drug: Ranolazine

Interventions

  • Metformin 1000 mg bid on Days 1-10

    Also known as: Glucophage

  • Ranolazine 500 mg bid on Days 6-10

    Also known as: Ranexa

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of metformin

    Time frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5 and 10

  2. Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin

    Time frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Days 5 and 10

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: From time of signed informed consent to time of follow-up phone call, an expected average of 5 weeks

  2. Maximum observed plasma concentration (Cmax) of ranolazine and metabolites

    Time frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 10

  3. Area under the plasma concentration versus time curve over the dosing interval, at steady state (AUCtau) of ranolazine and metabolites

    Time frame: 0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10 and 12 hours post-dose on Day 10

07

Study locations

1 site
  • SeaView Research Inc.
    Miami, Florida 33126, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2012
First posted
Mar 7, 2012
Start
Feb 2012
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Jul 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01546558
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Feb 2012
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Jul 11, 2012

Study contacts

Axel Juan, MD
principal investigator · SeaView Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Ranolazine

Start the discussion